Tedizolid population pharmacokinetics, exposure response, and target attainment

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 11, 2014, Pages 6462-6470

  Flanagan, S ^a   Passarell, J ^b   Lu, Q ^b   Fiedler Kelly, J ^b   Ludwig, E ^b   Prokocimer, P ^a  

^a Cubist ^*  (United States)

^b Albany Medical College   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; TEDIZOLID; ANTIINFECTIVE AGENT; ORGANOPHOSPHATE; OXAZOLE DERIVATIVE; OXAZOLIDINONE DERIVATIVE; PRODRUG; TETRAZOLE DERIVATIVE;

ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION; ADULT; AREA UNDER THE CURVE; ARTICLE; BACTERIAL SKIN DISEASE; BILIRUBIN BLOOD LEVEL; BODY WEIGHT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PLASMA CONCENTRATION-TIME CURVE; STEADY STATE; THROMBOCYTE COUNT; ADOLESCENT; AGED; BIOAVAILABILITY; BLOOD; DRUG EFFECTS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; NEUTROPHIL; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCAL INFECTIONS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEUTROPHILS; ORGANOPHOSPHATES; OXAZOLES; OXAZOLIDINONES; PLATELET COUNT; PRODRUGS; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCAL INFECTIONS; TETRAZOLES; YOUNG ADULT;

EID: 84908266611     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03423-14     Document Type: Article

References (21)

1. Prokocimer P, De Anda C, Fang E, Mehra P, Das A. 2013. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 309:559-569. http://dx.doi.org/10.1001/jama.2013.241.
2. Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P. 2014. Once-daily tedizolid for 6 days versus twice-daily linezolid for 10 days in acute bacterial skin and skin structure infections: results from a randomised controlled trial using an intravenous-to-oral switch strategy (ESTABLISH-2 study). Lancet Infect. Dis. 14:696-705. http://dx.doi.org/10.1016/S1473-3099(14)70737-6.
3. Prokocimer P, Bien P, Surber J, Mehra P, DeAnda C, Bulitta JB, Corey GR. 2011. Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections. Antimicrob. Agents Chemother. 55:583-592. http://dx.doi.org/10.1128/AAC.00076-10.
4. Shaw KJ, Poppe S, Schaadt R, Brown-Driver V, Finn J, Pillar CM, Shinabarger D, Zurenko G. 2008. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob. Agents Chemother. 52:4442-4447. http://dx.doi.org/10.1128/AAC.00859-08.
5. Flanagan S, Fang E, Muñoz KA, Minassian SL, Prokocimer PG. 2014. Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid. Pharmacotherapy 34:891-900. http://dx.doi.org/10.1002/phar.1458.
6. Sahre M, Sabarinath S, Grant M, Seubert C, DeAnda C, Prokocimer P, Derendorf H. 2012. Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers. Int. J. Antimicrob. Agents 40:51-54. http://dx.doi.org/10.1016/j.ijantimicag.2012.03.006.
7. Louie A, Liu W, Kulawy R, Drusano GL. 2011. In vivo pharmacodynamics of torezolid phosphate, a new oxazolidinone antibiotic, against methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains in a mouse thigh infection model. Antimicrob. Agents Chemother. 55: 3453-3460. http://dx.doi.org/10.1128/AAC.01565-10.
8. Drusano GL, Liu W, Kulawy R, Louie A. 2011. Impact of granulocytes on the antimicrobial effect of tedizolid in a mouse thigh infection model. Antimicrob. Agents Chemother. 55:5300-5305. http://dx.doi.org/10.1128/AAC.00502-11.
9. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. 2011. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 13: 143-151. http://dx.doi.org/10.1208/s12248-011-9255-z.
10. Hosmer DWJ, Lemeshow S. 2000. Applied logistic regression, 2nd ed. John Wiley & Sons, New York, NY.
11. Rana S, Midi H, Sarkar SK. 2012. Validation and performance analysis of binary logistic regression model, p 51-55. In Mastorakis N, Mladenov V, Zaharim A, Bulucea CA (ed), Proceedings of the WSEAS International Conference on Environment, Medicine and Health Sciences. United States Branch of the World Scientific and Engineering Academy and Society. http://www.wseas.us/e-library/conferences/2010/Penang/EMEH/EMEH-09.pdf. Accessed 28 March 2014.
12. Lodise TP, Drusano GL. 2014. Use of pharmacokinetic/pharmacodynamic systems analyses to inform dose selection of tedizolid phosphate. Clin. Infect. Dis. 57(Suppl 1):S28-S34. http://dx.doi.org/10.1093/cid/cit615.
13. Plock N, Buerger C, Joukhader C, Kljucar S, Kloft C. 2007. Does linezolid inhibit its own metabolism? Population pharmacokinetics as a tool to explain the observed nonlinearity in both healthy volunteers and septic patients. Drug Metab. Dispos. 35:1816-1823. http://dx.doi.org/10.1124/dmd.106.013755.
14. Meagher AK, Forrest A, Rayner CR, Birmingham MC, Schentag JJ. 2003. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob. Agents Chemother. 47:548-553. http://dx.doi.org/10.1128/AAC.47.2.548-553.2003.
15. Reference deleted.
16. Flanagan SD, Bien PA, Muñoz KA, Minassian SL, Prokocimer PG. 2014. Pharmacokinetics of tedizolid following oral administration: single and multiple dose, effect of food, and comparison of two solid forms of the prodrug, Pharmacotherapy 34:240-250. http://dx.doi.org/10.1002/phar.1337.
17. US Food and Drug Administration. 2013. Guidance for industry acute bacterial skin and skin structure infections: developing drugs for treatment. US Food and Drug Administration, Washington, DC. http://www.fda.gov/downloads/Drugs/./Guidances/ucm071185.pdf. Accessed 29 October 2013.
18. Flanagan S, Minassian SL, Morris D, Ponnuraj R, Marbury TC, Alcorn HW, Fang E, Prokocimer P. 2014. Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment. Antimicrob. Agents Chemother. 58:6471-6476. http://dx.doi.org/10.1128/AAC.03431-14.
19. European Medicines Agency. 15 December 2011. Guideline on the evaluation of medicinal products indicated for the treatment of bacterial infections. CPMP/EWP/558/95 rev 2. European Medicines Agency, London, United Kingdom. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003417.pdf. Accessed 16 April 2014.
20. European Medicines Agency. 24 October 2013. Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. EMA/CHMP/351889/2013. European Medicines Agency, London, United Kingdom. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2013/11/WC500153953.pdf. Accessed 16 April 2014.
21. Dreskin H, Muñoz KA, Fang E, Minassian SL, Subich D, Flanagan E, Prokocimer P. 2012. Safety and pharmacokinetics of single dose administration of tedizolid phosphate in healthy elderly subjects and adult control subjects. Abstr. 52nd Intersci. Conf. Antimicrob. Agents Chemother., abstr A-1293.